New insider activity at LifeMD ( (LFMD) ) has taken place on March 18, 2025.
Jessica Friedeman, the Chief Marketing Officer of LifeMD, has recently sold 30,000 shares of the company’s stock, amounting to a total transaction value of $169,500.
Recent Updates on LFMD stock
In the last 24 hours, LifeMD’s stock has seen positive developments following its Q4 earnings report, which surpassed expectations with a 43% year-over-year revenue increase to $64.3 million, driven by a 60% rise in telehealth revenue. Analyst Yi Chen from H.C. Wainwright raised the price target for LifeMD, citing the company’s comprehensive care platform and pharmacy benefits infrastructure that facilitate access to branded GLP-1 medications. The company’s strategic product launches, including male hormone replacement therapy and expanded Medicare offerings, are expected to drive future growth. However, challenges such as declining gross margins and uncertainties in the compounded GLP-1 medication market were noted. Despite these challenges, LifeMD’s forward-looking guidance for 2025 remains optimistic, with projected revenues between $265 million and $275 million.
More about LifeMD
YTD Price Performance: 13.58%
Average Trading Volume: 1,176,256
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $264.8M